Related Experiment Video
Updated: Aug 8, 2026
High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
Low-dose "natural" alpha-interferon in B-cell derived chronic lymphocytic leukemia
G Pozzato1, F Franzin, M Moretti
1Istituto di Patologia Medica, Facoltà di Medicina, Università di Trieste, Italy.
Insights
Low-dose natural alpha-interferon (IFN) effectively reduced lymphocyte counts in early-stage chronic lymphocytic leukemia (CLL) patients. This treatment was well-tolerated, showing promise for managing CLL with minimal side effects.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Alpha-interferon (alpha-IFN) demonstrates antiproliferative effects in early chronic lymphocytic leukemia (CLL).
- Recombinant alpha-IFN can cause significant adverse effects.
- Natural, low-dose IFN offers a potentially safer alternative for CLL treatment.
Purpose of the Study:
- To evaluate the efficacy and safety of low-dose natural alpha-interferon in patients with early-stage B-cell CLL.
- To assess the impact of natural IFN on lymphocyte counts in CLL patients.
- To determine the tolerability of natural IFN therapy in this patient population.
Main Methods:
- A cohort of fifteen patients with B-cell chronic lymphocytic leukemia (B-CLL), stage A (Binet classification), received treatment.
- The treatment regimen involved natural IFN at a dose of 1 MU administered three times weekly for six months.
Main Results:
- Lymphocyte counts significantly decreased from a baseline of 13,050 +/- 3,200 to 7,500 +/- 2,940 within the six-month treatment period.
- One patient exhibited no response to the IFN therapy.
- No adverse side effects were reported by any of the patients during the study.
Conclusions:
- Low-dose natural alpha-interferon appears to be a beneficial and well-tolerated therapeutic option for early-stage CLL.
- Further research is required to establish the definitive curative potential of IFN in the management of CLL.
Background:
Alpha-interferon (alpha-IFN) was found to have a good antiproliferative effect in early stage chronic lymphocytic leukemia (CLL), but recombinant alpha-IFN administration may induce serious side effects. Therefore low-dose "natural" IFN was evaluated in terms of efficacy and safety.
Methods:
Fifteen patients affected by stage A (according to Binet) B-CLL underwent the treatment: natural IFN 1 MU three times a week for 6 months.
Results:
Overall lymphocyte count decreased from 13,050 +/- 3,200 to 7,500 +/- 2,940 within 6 months. One patient did not respond to IFN therapy. No one complained of side effects.
Conclusion:
Low dose "natural" alpha-IFN seems useful and well tolerated in CLL, but the potential curative role of IFN in CLL remains to be established.
